Stuttering Therapy: FDA Approval & Dr. McGuire’s Research

Summary of the Article:

This⁣ article details the founding and mission of the Stuttering Treatment and Research Society (STARS), and explores the current state of stuttering treatment and research. Here’s a breakdown of⁢ the key points:

* Unmet⁣ Need: Stuttering affects a meaningful portion of the population (1% of adults, 4% of children) yet lacks FDA-approved treatments despite being recognized in⁢ both the ICD and DSM.
* STARS’ Mission: Founded by Gerald McGuire,⁤ MD, STARS⁢ aims to raise awareness, improve physician education, and drive research into effective stuttering treatments. ⁢⁣ It was created due to the medical ⁤community ⁤largely ignoring the condition.
*⁣ neurological Basis: ⁢Stuttering is understood to have neurological underpinnings, often linked to basal ganglia dysfunction and dopaminergic signaling.
* Current Treatments: While some speech therapy can definitely help children, adult treatment options are limited. ⁢ Physicians need to be aware of medications for co-occurring conditions (ADHD, OCD, tic ⁣disorders) that can worsen stuttering.
* Comorbidities: Stuttering frequently occurs alongside other conditions like ADHD, OCD, social anxiety, and tics,‍ and addressing these ‍is crucial for⁤ effective treatment.
* Complexity of Stuttering: The article emphasizes that stuttering is ⁣a complex condition with varying⁣ causes, courses, and comorbidities, requiring individualized approaches.
* Past Context: Stuttering has existed throughout history, ⁣even affecting prominent figures like Demosthenes, highlighting the long-standing ⁢need for effective solutions.

In essence, the article highlights the‍ significant⁢ gap in care for individuals who stutter and the importance of STARS in advocating for research and improved understanding of⁢ this frequently enough-overlooked neurodevelopmental disorder.